← Leaderboards
Qiang Gong
Aptitude Medical Systems, Inc.
$6,642,924
Attributed
$6,642,924
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2014–23$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,642,924 · 8
By mechanism
R44$5,671,816 · 4
R43$971,108 · 4
Top collaborators
No co-investigators on record.
Most similar at Aptitude Medical Systems, Inc.
Same institution · by research overlap
- Jinpeng Wang$2,751,007
Others in their field
Top investigators on “Performance”
- Jeffrey P Krischer · University Of South Florida$413,069,911
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$378,749,497
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Lawrence Corey · Fred Hutchinson Cancer Center$319,618,139
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
Research focus
PerformanceAffinityParticleAptamerCostSmall Business Innovation Research GrantVascular Endothelial Growth FactorsReportingBiologicalCombined Modality TherapyNucleic AcidsBlindnessPharmaceutical PreparationsPre-ClinicalSafetyDoseBindingAngiogenesisIntravitreal InjectionSamplingAptitudeComplementProgramsBase
Grant awards (14)
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$755,521
R44 · FY2023 · EY · contact PI
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$744,393
R44 · FY2022 · EY · contact PI
Targeting SDF-1 for effective wet AMD treatment$805,217
R44 · FY2021 · EY · contact PI
Developing a multivalent agent for long-lasting treatment of diabetic macular edema$224,653
R44 · FY2021 · EY · contact PI
Targeting SDF-1 for effective wet AMD treatment$911,698
R44 · FY2020 · EY · contact PI
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$224,973
R44 · FY2020 · EY · contact PI
Targeting SDF-1 for effective wet AMD treatment$282,661
R44 · FY2019 · EY · contact PI
Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy$224,946
R43 · FY2019 · EY · contact PI
Topical delivery of therapeutic aptamers$293,239
R43 · FY2018 · EB · contact PI
Targeting SDF-1 for effective wet AMD treatment$250,102
R43 · FY2017 · EY · contact PI
Fully modified bispecific aptamer for effective wet AMD combination treatment$202,821
R43 · FY2017 · EY · contact PI
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$625,303
R44 · FY2016 · GM · contact PI
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$872,697
R44 · FY2015 · GM · contact PI
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$224,700
R44 · FY2014 · GM · contact PI